Keith Skubitz, MD

Professor of Medicine, Division of Hematology, Oncology and Transplantation

Keith Skubitz

Contact Info

Mailing Address:
420 Delaware ST SE
MMC 480
Minneapolis, MN 55455

Administrative Assistant Name
Pamela Hansen

Administrative Phone

Administrative Email

Administrative Fax Number

Professor of Medicine, Division of Hematology, Oncology and Transplantation

Hematologist / Oncologist

Medical School, Johns Hopkins University School of Medicine, Baltimore, MD

Residency, University of Minnesota, Minneapolis, MN

Fellowship, Johns Hopkins University, Baltimore, MD

Fellowship, University of Minnesota, Minneapolis, MN


Dr. Skubitz has led the medical oncology arm of the Bone and Soft Tissue Tumor program at the University since 1988. He received an AB in physics and chemistry from Cornell University and an MD from the Johns Hopkins University School of Medicine, and then did internal medicine training at the University of Minnesota. He completed two fellowships, one in Clinical Pharmacology at Johns Hopkins and one in Medical Oncology at the University of Minnesota.

Awards & Recognition

  • Phi Kappa Phi
  • International Who's Who of Professionals (1996-present)
  • Inventor Recognition Award, University of Minnesota (2005, 2008)
  • Top 1% of Most-Cited Investigators in Biosciences (2005)

Professional Associations

  • Head, Medical Oncology Arm of the Bone and Soft Tissue Tumor Program
  • Member, American Association for the Advancement of Science
  • Member, American Society of Hematology
  • University of Minnesota Sarcoma Executive Committee (2009-present)


Research Summary/Interests

Dr. Skubitz cares for patients with a variety of malignancies and related diseases. His research primarily involves drug development and clinical trials, including the use of genomics to identify new drug targets and predict disease outcome.


  • Skubitz KM, Francis P, Skubitz AP, Luo X, Nilbert M. Gene expression identifies heterogeneity of
  • metastatic propensity in high-grade soft tissue sarcomas. Cancer. 2012; 118(17):4235-43.
  • Benjamin R, Schoffski P, Hartmann JT, van Oosterom A, Bui BN, Duyster J, Schuetze S, Blay J, Reichardt
    P, Rosen L, Skubitz K, McCoy S, Sun YN, Stepan D, Baker L. Efficacy and safety of motesanib, an oral
    inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal
    tumors., Cancer Chemother Pharmacol Jul;68(1):69-77, 2011.
  • Skubitz KM, Skubitz AP. Two new synthetic peptides from the N-domain of CEACAM1 (CD66a)
    stimulate neutrophil adhesion to endothelial cells. Biopolymers. 96(1):25-31, 2010.
  • Thomas DM, Henshaw R, Skubitz KM, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W,
    Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
    Lancet Oncol 11:275-280, 2010.
  • Thomas DM, Skubitz KM. Giant cell tumour of bone. Curr Opin Oncol. 2009 Jul;21(4):338-44. Review.
  • Skubitz KM. Neutrophilic Leukocytes, in Wintrobe's Clinical Hematology, Twefth Edition, ed Lee GR,
    Foerster J, Greer J, Lukens J, Rodgers G, Paraskevas F, Williams and Wilkins, Baltimore, p.170-213,
  • Skubitz KM, Skubitz AP. Interdependency of CEACAM-1, -3, -6, and -8 induced human neutrophil
    adhesion to endothelial cells. J Transl Med. 2008; 6:78.
  • Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP. Identification of heterogeneity among soft tissue
    sarcomas by gene expression profiles from different tumors. J Transl Med. 2008; 6:23.
  • Skubitz KM, D’Adamo DR. Sarcoma. Mayo Clin. Proc., 82(11):1409-1432, 2007.
  • Skubitz KM, Zimmerman W, Kammerer R, Pambuccian S, Skubitz AP. Differential gene expression
    identifies subgroups of renal cell carcinoma. J Lab Clin Med. 2006; 147:250-67.



  • Cancer
  • Hematology/Oncology
  • Medical Oncology


Masonic Cancer Center

Clinical Interests

Variety of malignancies and related diseases including sarcomas and kidney cancer; Bone and soft tissue cancer